Cellular and Molecular Life Sciences CMLS

, Volume 61, Issue 7–8, pp 750–762 | Cite as

Aldose reductase structures: implications for mechanism and inhibition

  • O. El-Kabbani
  • F. Ruiz
  • C. Darmanin
  • R. P.-T. Chung
Multi-author Review

Abstract

During chronic hyperglycaemia, elevated vascular glucose level causes increased flux through the polyol pathway, which induces functional and morphological changes associated with secondary diabetic complications. Inhibitors of aldose reductase (ARIs) have been widely investigated as potential therapeutic agents, but to date only epalrestat is successfully marketed for treatment of diabetic neuropathy, in Japan. Promising compounds during in vitro studies or in trials with animal models have failed to proceed beyond clinical trials and to everyday use, due to a lack of efficacy or adverse side effects attributed to lack of inhibitor specificity and likely inhibition of the related aldehyde reductase (ALR1). Knowledge of the catalytic mechanism and structures of the current inhibitors complexed with ALR2 are means by which more specific and tightly bound inhibitors can be discovered. This review will provide an overview of the proposed catalytic mechanism and the current state of structure-based drug design.

Aldose reductase mechanism inhibitors drug design aldehyde reductase 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Birkhäuser-Verlag Basel 2004

Authors and Affiliations

  • O. El-Kabbani
    • 1
  • F. Ruiz
    • 1
  • C. Darmanin
    • 1
  • R. P.-T. Chung
    • 1
  1. 1.Department of Medicinal Chemistry, Victorian College of PharmacyMonash UniversityParkvilleAustralia

Personalised recommendations